SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2019 / Cilt: 44 - Sayı: 4

Investigating the impact of polysomy 17 in breast cancer patients with HER2 amplification through meta-analysis

HER2 amplifikasyonu olan meme kanseri hastalarında Polizomi 17’nin etkisinin meta-analiz ile araştırılması

Elif PALA
Şebnem SAĞ
İlker ERCAN
Ezel Özge TAŞ
Pages
411–416
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It was observed that in terms of lymph node involvement, P17 was a risk factor in patients and with regard to tumor grade, P17 was a risk factor when grade increased in patients with amplification.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Since studies regarding the effect of polysomy 17 (P17) in breast cancer cases with some specific clinical findings are few in number and are in small sample sizes, meta-analysis was implemented to exhibit the effectsof P17 in patients with Human Epidermal growth factor Receptor 2 (HER2) amplification on lymph node involve- ment and tumor grade.Materials and methods: Pubmed literature database was scanned up to June 2017 by using the keywords “poly- somy 17 breast cancer” and 141 studies were accessed.
📊
Key Findings & Data:Ultimately four of the reviewed papers have been found to be appropriate for examining the effect of P17 on lymph node involvement and tumor grade.
💡
Conclusion & Impact:Conclusion: It was observed that in terms of lymph node involvement, P17 was a risk factor in patients and with regard to tumor grade, P17 was a risk factor when grade increased in patients with amplification.
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Since studies regarding the effect of polysomy 17 (P17) in breast cancer cases with some specific clinical findings are few in number and are in small sample sizes, meta-analysis was implemented to exhibit the effectsof P17 in patients with Human Epidermal growth factor Receptor 2 (HER2) amplification on lymph node involve- ment and tumor grade.Materials and methods: Pubmed literature database was scanned up to June 2017 by using the keywords “poly- somy 17 breast cancer” and 141 studies were accessed. Ultimately four of the reviewed papers have been found to be appropriate for examining the effect of P17 on lymph node involvement and tumor grade. Prior to meta-analy- sis, publication bias and heterogeneity of the studies was examined.Results: Meta-analysis in the examining the effect of poly- somy 17 on lymph node involvement (OR  1.708, 95% CI: 1.068–2.733), on grade [3]/[3,1] (OR  3.402, 95% CI: 1.726–6.707), on grade [3]/[3, 2] (OR  2.581, 95% CI: 0.778–8.559)and on grade [2]/[2,1] (OR  1.854, 95% CI: 0.531–6.468) was determined in those with HER2 amplification. Conclusion: It was observed that in terms of lymph node involvement, P17 was a risk factor in patients and with regard to tumor grade, P17 was a risk factor when grade increased in patients with amplification.

Özet

Amaç: Bazı spesifik klinik bulgulara sahip meme kanseri vakalarında polisomi 17’nin (P17) etkisine ilişkin çalış- malar az sayıda ve küçük örneklem boyutlarında olması nedeniyle, İnsan Epidermal Büyüme Faktörü Reseptör 2 (HER2) amplifikasyonu olan hastalarda P17’nin lenf nodu tutulumu ve tümör evresi üzerindeki etkilerini ortaya koymak amacıyla meta-analiz uygulanmıştır. Gereç ve Yöntem: Pubmed literatür veri tabanı, 2017 yılının haziran ayına kadar “polysomy 17 meme kanseri” anahtar sözcükleri kullanılarak tarandı ve 141 çalışmaya erişildi. Gözden geçirilen çalışmalardan dördünün P17’nin lenf nodu tutulumu ve tümör evresi üzerindeki etkisini incele- mek için uygun olduğu tespit edildi. Meta-analizden önce, çalışmaların yayın yanlılığı ve heterojenitesi incelendi. Bulgular: Yapılan meta-analiz sonucunda HER2 ampli- fikasyonu olan hastalarda, P17’nin lenf nodu tutulumu (OR  1.708, 95% CI: 1.068–2.733), evre [3]/[3,1] (OR  3.402, 95% CI: 1.726–6.707), evre [3]/[3,2] (OR  2.581, 95% CI: 0.778–8.559) ve evre [2]/[2,1] (OR  1.854, 95% CI: 0.531– 6.468) üzerindeki etkisi belirlendi. Sonuç: Lenf nodu tutulumu açısından P17’nin amplifikas- yonu olan hastalarda risk faktörü olduğu, tümör evresi göz önüne alındığında ise, amplifikasyonu olan hasta- larda P17’nin evre yükseldikçe bir risk faktörü olduğu tes- pit edilmiştir.

🔖

Cite This Article

PALA, E., SAĞ, Ş., ERCAN, İ., TAŞ, E. Ö. (2022). Investigating the impact of polysomy 17 in breast cancer patients with HER2 amplification through meta-analysis. Türk Biyokimya Dergisi, Cilt: 44 - Sayı: 4, 411–416. https://ajindex.com/articles/620902

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30
  2. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331–40
  3. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114–22
  4. Brant SR. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 2011;17:1–5
  5. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989;135:921–30
  6. Noel LH, Geffriaud C, Chauveau D, Houhou S, Landais P, Kirhaoui F, et al. Antineutrophil cytoplasm antibodies: diversity and clini- cal applications. Adv Nephrol Necker Hosp 1993;22:237–67
  7. Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 2009;24:202–8
  8. Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflam- mation and colorectal cancer: a double-edged sword? World J Gastroenterol 2011;17:3092–100
  9. Liang P, Pardee AB. Analysing differential gene expression in cancer. Nat Rev Cancer 2003;3:869–76
  10. Dudley JT, Tibshirani R, Deshpande T, Butte AJ. Disease signa- tures are robust across tissues and experiments. Mol Syst Biol 2009;5:307
  11. Mesko B, Poliska S, Szegedi A, Szekanecz Z, Palatka K, Papp M, et al. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med Genomics 2010;3:15
  12. Chang KC, Komm B, Arnold NB, Korc M. The application of differential display as a gene profiling tool. Methods Mol Biol 2007;383:31–40
  13. Zuo L, Ogle CK, Fischer JE, Nussbaum MS. mRNA differential display of colonic mucosa cells in ulcerative colitis. J Surg Res 1997;69:119–27
  14. Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, et al. Identification of prostate cancer mRNA markers by aver- aged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A 2007;104:2343–8
  15. Stein J, Liang P. Differential display technology: a general guide. Cell Mol Life Sci 2002;59:1235–40
  16. Mirza AH, Kaur S, Brorsson CA, Pociot F. Effects of GWAS-associ- ated genetic variants on lncRNAs within IBD and T1D candidate loci. PLoS One 2014;9:e105723
  17. Parkin DM, Bray F, Ferlay J